PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS
申请人:MERCK FROSST CANADA INC.
公开号:EP0639181A1
公开(公告)日:1995-02-22
THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA
申请人:VITAE PHARMACEUTICALS, INC.
公开号:US20170008910A1
公开(公告)日:2017-01-12
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR
. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
US5506227A
申请人:——
公开号:US5506227A
公开(公告)日:1996-04-09
[EN] PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS<br/>[FR] ALCOOLS BENZYLIQUES SUBSTITUES PAR PYRIDINE EN TANT QU'ANTAGONISTES DES LEUCOTRIENES
申请人:MERCK FROSST CANADA INC.
公开号:WO1993021158A1
公开(公告)日:1993-10-28
(EN) Compounds having formula (I) are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.(FR) Des composés selon la formule (I) sont des antagonistes des actions des leucotriènes. Ces composés sont utiles en tant qu'agents antiasthmatiques, antiallergiques, anti-inflammatoires et cytoprotecteurs. Ils sont également utiles dans le traitement de l'angine du spasme cérébral, de la néphrite glomérulaire, de l'hépatite, de l'endotoxémie, de l'uvéite et du rejet allogreffe.
[EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
申请人:GLAXO GROUP LTD
公开号:WO2011012622A1
公开(公告)日:2011-02-03
The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.